Actavis snapped up Chicago-based Durata Therapeutics to gain a next-generation antibiotic to treat skin infections. On October 6 Actavis agreed to pay $675 million in cash and up to $146.5 million in milestones if Durata's new drug Dalvance (dalbavancin) meets regulatory and sales goals. With the deal, Parsippany, New Jersey–based Actavis expands its point-of-care, anti-infective franchise in competition with Lexington, Massachusetts–based Cubist Pharmaceuticals. Dalvance, approved in May 2014 (Nat. Biotechnol. 32, 603, 2014), is a second-generation glycopeptide dosed once a week for two weeks to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Rights and permissions
About this article
Cite this article
$675 million for MRSA antibiotic. Nat Biotechnol 32, 1070 (2014). https://doi.org/10.1038/nbt1114-1070c
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1114-1070c